TLDR ENERGI-F701 solution was found to be more effective and safer than Regaine® 2% minoxidil solution in treating female pattern hair loss, with increased hair density and less side effects.
In this study, researchers compared the efficacy and safety of ENERGI-F701 solution to Regaine® 2% minoxidil solution for treating female pattern hair loss (FPHL). The study included 67 women with FPHL who were randomly assigned to either the ENERGI-F701 or Regaine® group. The results showed that both groups significantly increased hair density at week 12. The ENERGI-F701 group also had a significant reduction in all-day shed hair count at weeks 4 and 6, as well as a lower percentage of local skin reactions compared to the Regaine® group. Additionally, the ENERGI-F701 group had greater increases in hair density and thickness, as well as better scores on the investigator photographic assessment questionnaire and the female hair loss quality of life questionnaire. Overall, the ENERGI-F701 solution was found to be effective in treating FPHL without initial hair shedding compared to the Regaine® 2% minoxidil solution.
3 citations
,
January 2022 in “Journal of The American Academy of Dermatology” 1 mg/day of low-dose oral minoxidil is effective and safe for treating female hair loss.
September 2021 in “Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature” 
2 citations
,
October 2020 in “Dermatologic Therapy” Herbal solution improves hair diameter and density more than 5% minoxidil for androgenetic alopecia.
1 citations
,
August 2018 in “Journal of The American Academy of Dermatology” Combination of minoxidil and finasteride is more effective in increasing hair diameter than minoxidil alone for female-pattern hair loss.
82 citations
,
March 1994 in “Archives of Dermatology” 2% topical minoxidil effectively treats female hair loss with minimal side effects.
85 citations
,
December 1990 in “Journal of Investigative Dermatology” Minoxidil promotes hair growth in women with early-stage alopecia.
16 citations
,
July 1988 in “International Journal of Dermatology” A 48-week double-blind study involving 428 patients evaluated the safety and efficacy of a 2% minoxidil solution for treating male pattern baldness. Initially, patients received either the minoxidil solution or a placebo for 24 weeks, after which placebo patients switched to minoxidil. By the end of the placebo-controlled period, 384 patients were evaluable, and 329 completed the study. Results showed that the 2% minoxidil group had a significantly higher mean nonvellus hair count compared to the placebo group (p = 0.0187) and a greater increase in nonvellus hair from baseline to week 24 (p = 0.0385). From weeks 24 to 48, both groups experienced a significant increase in nonvellus hair count. Assessments by patients and investigators indicated significant differences in hair growth between treatments at week 24, with more hair growth observed in the minoxidil group.
